KRAS as a Therapeutic Target.

Authors:
Frank McCormick

Clin Cancer Res 2015 Apr;21(8):1797-801

Frederick National Laboratory for Cancer Research, Frederick, Maryland. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by identifying targets that KRAS cancers depend on for survival. Although drugs that block the well-established downstream pathways, RAF-MAPK and PI3K, are being tested in the clinic, new efforts are under way to exploit previously unrecognized vulnerabilities, such as altered metabolic networks, or novel pathways identified through synthetic lethal screens. Furthermore, new ways of suppressing KRAS gene expression and of harnessing the immune system offer further hope that new ways of treating KRAS are finally coming into view. These issues are discussed in this edition of CCR Focus.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407814PMC
April 2015
30 Reads

Publication Analysis

Top Keywords

kras
8
tested clinic
4
pi3k tested
4
raf-mapk pi3k
4
clinic efforts
4
pathways raf-mapk
4
efforts exploit
4
altered metabolic
4
metabolic networks
4
vulnerabilities altered
4
unrecognized vulnerabilities
4
exploit unrecognized
4
downstream pathways
4
block well-established
4
processing identifying
4
identifying targets
4
kras processing
4
blocking kras
4
ways blocking
4
targets kras
4

Similar Publications